Effects of sitagliptin on coronary atherosclerosis evaluated using integrated backscatter intravascular ultrasound in patients with type 2 diabetes: rationale and design of the TRUST study

Heart and Vessels

Volumn 31, Issue 5, 2016, Pages 649-654

  Nozue, Tsuyoshi ^a   Fukui, Kazuki ^b   Koyama, Yutaka ^c   Fujii, Hiroyuki ^d   Kunishima, Tomoyuki ^e   Hikita, Hiroyuki ^f   Hibi, Kiyoshi ^g   Miyazawa, Akiyoshi ^h   Michishita, Ichiro ^a  

^a YOKOHAMA SAKAE KYOSAI HOSPITAL   (Japan)

^b Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center Hospital   (Japan)

^c Cardiovascular Center Synthesis Shinkawahashi Hospital   (Japan)

^d Yokohama Minami Kyosai Hospital   (Japan)

^e TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f YOKOSUKA KYOSAI HOSPITAL   (Japan)

^g YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^h Cardiocore Japan   (Japan)

Author keywords

Coronary atherosclerosis; Diabetes mellitus; Dipeptidyl peptidase 4 inhibitor; Intravascular ultrasound; Sitagliptin

Indexed keywords

ANTIDIABETIC AGENT; GLIMEPIRIDE; SITAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INCRETIN;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; FOLLOW UP; HUMAN; INTRAVASCULAR ULTRASOUND; INTRAVASCULAR ULTRASOUND SYSTEM; JAPAN; MAJOR CLINICAL STUDY; METHODOLOGY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPLICATION; CORONARY BLOOD VESSEL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIAGNOSTIC IMAGING; DRUG EFFECTS; INTERVENTIONAL ULTRASONOGRAPHY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; TIME FACTOR;

CLINICAL PROTOCOLS; CORONARY ARTERY DISEASE; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; INCRETINS; JAPAN; PERCUTANEOUS CORONARY INTERVENTION; PLAQUE, ATHEROSCLEROTIC; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RESEARCH DESIGN; SITAGLIPTIN PHOSPHATE; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84925432914     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-015-0662-4     Document Type: Article

References (32)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234
2. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM (2004) Pravastatin or Atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators, intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504
3. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK (2005) Treating to new targets (TNT) investigators, intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425–1435
4. Oikawa S, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Nakaya N, Saito Y, Sasaki J, Shimamoto K, Itakura H, J-LIT Study Group (2007) Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: implication from Japan lipid intervention trial (J-LIT). Atherosclerosis 191:440–446
5. Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, Kunishima T, Sato A, Nozato T, Miyake S, Takeyama Y, Morino Y, Yamauchi T, Muramatsu T, Hibi K, Terashima M, Michishita I, Investigators TRUTH (2012) Impact of diabetes mellitus on coronary atherosclerosis and plaque composition under statin therapy —subanalysis of the TRUTH study. Circ J 76:2188–2196
6. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M, Investigators JAPAN-ACS (2010) Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome—serial intravascular ultrasound observations from the Japan Assessment of pitavastatin and atorvastatin in acute coronary syndrome trial (the JAPAN-ACS Trial). Circ J 74:1165–1174
7. Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon KW, Sipahi I, Schoenhagen P, Nissen SE (2008) Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol 52:255–262
8. Kaneko H, Yajima J, Oikawa Y, Tanaka S, Fukamachi D, Suzuki S, Sagara K, Otsuka T, Matsuno S, Kano H, Uejima T, Koike A, Nagashima K, Kirigaya H, Sawada H, Aizawa T, Yamashita T (2014) Long-term incidence and prognostic factors of the progression of new coronary lesions in Japanese coronary artery disease patients after percutaneous coronary intervention. Heart Vessel 29:437–442
9. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Jr Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559
10. Nissen SE, Yock P (2001) Intravascular ultrasound: novel pathophysiological insights and current clinical applications. Circulation 103:604–616
11. Kawasaki M, Takatsu H, Noda T, Sano K, Ito Y, Hayakawa K, Tsuchiya K, Arai M, Nishigaki K, Takemura G, Minatoguchi S, Fujiwara T, Fujiwara H (2002) In vivo quantitative tissue characterization of human coronary arterial plaques by use of integrated backscatter intravascular ultrasound and comparison with angioscopic findings. Circulation 105:2487–2492
12. Kawasaki M, Bouma BE, Bressner J, Houser SL, Nadkarni SK, MacNeill BD, Jang IK, Fujiwara H, Tearney GJ (2006) Diagnostic accuracy of optical coherence tomography and integrated backscatter intravascular ultrasound images for tissue characterization of human coronary plaques. J Am Coll Cardiol 48:81–88
13. Iwama M, Tanaka S, Noda T, Segawa T, Kawasaki M, Nishigaki K, Minagawa T, Watanabe S, Minatoguchi S (2014) Impact of tissue characteristics on luminal narrowing of mild angiographic coronary stenosis: assessment of integrated backscatter intravascular ultrasound. Heart Vessel 29:750–760
14. Kumagai S, Takashima H, Waseda K, Ando H, Suzuki A, Uetani T, Harada K, Yoshida T, Kunimura A, Shimbo Y, Kitagawa K, Harada K, Ishii H, Yoshikawa D, Matsubara T, Murohara T, Amano T (2014) Prognostic impact of lipid contents on the target lesion in patients with drug eluting stent implantation. Heart Vessel 29:761–768
15. Nomiyama T, Akehi Y, Takenoshita H, Nagaishi R, Terawaki Y, Nagasako H, Kudo T, Kodera T, Kobayashi K, Urata H, Yanase T (2012) Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 95:e27–e28
16. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A (2004) Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287:1209–1215
17. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H (2010) Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59:1030–1037
18. Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y (2011) DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 58:157–166
19. Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R, Sun Q, Mihai G, Maiseyeu A, Rajagopalan S (2011) Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 124:2338–2349
20. Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S (2013) Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol 12:125
21. Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohba K, Konishi M, Maeda H, Izumiya Y, Kaikita K, Sumida H, Jinnouchi H, Matsui K, Kim-Mitsuyama S, Takeya M, Ogawa H (2012) A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 59:265–276
22. Nakamura K, Oe H, Kihara H, Shimada K, Fukuda S, Watanabe K, Takagi T, Yunoki K, Miyoshi T, Hirata K, Yoshikawa J, Ito H (2014) DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol 13:110
23. Terawaki Y, Nomiyama T, Kawanami T, Hamaguchi Y, Takahashi H, Tanaka T, Murase K, Nagaishi R, Tanabe M, Yanase T (2014) Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury. Cardiovasc Diabetol 13:154
24. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I (2013) SAVOR-TIMI 53 steering committee and investigators, saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326
25. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, EXAMINE Investigators (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335
26. Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H, Ogawa H (2013) Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J 77:1337–1344
27. Engel SS, Round E, Golm GT, Kaufman KD, Goldstein BJ (2013) Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. Diabetes Ther 4:119–145
28. Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA (2008) Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 48:592–598
29. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, Pinto FJ, Rosenfield K, Siegel RJ, Tuzcu EM, Yock PG (2001) American College of cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American College of cardiology task force on clinical expert consensus documents. J Am Coll Cardiol 37:1478–1492
30. Schoenhagen P, Sapp SK, Tuzcu EM, Magyar WA, Popovich J, Boumitri M, Vince DG, Crowe T, Nissen SE (2003) Variability of area measurements obtained with different intravascular ultrasound catheter systems: impact on clinical trials and a method for accurate calibration. J Am Soc Echocardiogr 16:277–284
31. Nakayama T, Komiyama N, Yokoyama M, Namikawa S, Kuroda N, Kobayashi Y, Komuro I (2010) Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. Int J Cardiol 138:157–165
32. Oyama J, Ishizu T, Sato Y, Kodama K, Bando YK, Murohara T, Node K (2014) Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: prologue study. Int J Cardiol 174:383–384